Ginkgo Bioworks Holdings


Prices are adjusted according to historical splits.

Ginkgo Bioworks Holdings Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.44 billion
Book Value:
Revenue TTM:
$390.00 million
Operating Margin TTM:
Gross Profit TTM:
$273.49 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Ginkgo Bioworks Holdings had its IPO on 2021-04-19 under the ticker symbol DNA.

The company operates in the Healthcare sector and Biotechnology industry. Ginkgo Bioworks Holdings has a staff strength of 1,292 employees.

Stock update

Shares of Ginkgo Bioworks Holdings opened at $2.08 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.04 - $2.17, and closed at $2.07.

This is a -0.96% slip from the previous day's closing price.

A total volume of 12,186,806 shares were traded at the close of the day’s session.

In the last one week, shares of Ginkgo Bioworks Holdings have slipped by -8%.

Ginkgo Bioworks Holdings's Key Ratios

Ginkgo Bioworks Holdings has a market cap of $3.44 billion, indicating a price to book ratio of 2.4609 and a price to sales ratio of 5.9899.

In the last 12-months Ginkgo Bioworks Holdings’s revenue was $390.00 million with a gross profit of $273.49 million and an EBITDA of $-1692385024. The EBITDA ratio measures Ginkgo Bioworks Holdings's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ginkgo Bioworks Holdings’s operating margin was -447.9% while its return on assets stood at -48.79% with a return of equity of -106.7%.

In Q1, Ginkgo Bioworks Holdings’s quarterly earnings growth was a positive 0% while revenue growth was a negative 52.1%.

Ginkgo Bioworks Holdings’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ginkgo Bioworks Holdings’s profitability.

Ginkgo Bioworks Holdings stock is trading at a EV to sales ratio of 4.334 and a EV to EBITDA ratio of -0.6303. Its price to sales ratio in the trailing 12-months stood at 5.9899.

Ginkgo Bioworks Holdings stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$2.42 billion
Total Liabilities
$191.70 million
Operating Cash Flow
Capital Expenditure
$19.44 million
Dividend Payout Ratio

Ginkgo Bioworks Holdings ended 2024 with $2.42 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.42 billion while shareholder equity stood at $1.61 billion.

Ginkgo Bioworks Holdings ended 2024 with $174.82 million in deferred long-term liabilities, $191.70 million in other current liabilities, 194000.00 in common stock, $-4602628000.00 in retained earnings and $58.73 million in goodwill. Its cash balance stood at $1.21 billion and cash and short-term investments were $1.21 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.

Ginkgo Bioworks Holdings’s total current assets stands at $1.33 billion while long-term investments were $121.75 million and short-term investments were $0. Its net receivables were $84.84 million compared to accounts payable of $21.57 million and inventory worth $2.51 million.

In 2024, Ginkgo Bioworks Holdings's operating cash flow was $-19414000.00 while its capital expenditure stood at $19.44 million.

Comparatively, Ginkgo Bioworks Holdings paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Ginkgo Bioworks Holdings stock is currently trading at $2.07 per share. It touched a 52-week high of $4.91 and a 52-week low of $4.91. Analysts tracking the stock have a 12-month average target price of $4.46.

Its 50-day moving average was $2.04 and 200-day moving average was $1.69 The short ratio stood at 11.05 indicating a short percent outstanding of 0%.

Around 920.8% of the company’s stock are held by insiders while 7373.2% are held by institutions.

Frequently Asked Questions About Ginkgo Bioworks Holdings

The stock symbol (also called stock or share ticker) of Ginkgo Bioworks Holdings is DNA

The IPO of Ginkgo Bioworks Holdings took place on 2021-04-19

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.


27 Drydock Avenue, Boston, MA, United States, 02210